Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome
Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome
This study will evaluate the safety and efficacy of Pregabalin (Lyrica) in treating patients
 with Restless Legs Syndrome (RLS) in a double-blind, placebo-controlled trial.
Inclusion Criteria:

 1. Outpatients with RLS diagnosed by a movement disorder specialist/ Sleep specialist .

 2. Patients must report some degree of pain which occurs on a regular basis.

 3. Age 18 years to 80 years.

 4. Women of child-bearing potential must use a reliable method of contraception and must
 provide a negative pregnancy test at entry into the study.

 5. Stable doses of all medications for 30 days prior to study entry and for the duration
 of the study.

 6. Willing and able to provide informed consent.

 7. Willing to comply with protocol. -

 Exclusion Criteria:

 1. Any illness that in the investigator's opinion preclude participation in this study.

 2. Pregnancy or lactation.

 3. Concurrent participation in another clinical study.

 4. Current treatment with a dopamine agonist (unless stopped at least 2 weeks prior to
 baseline).

 5. Dementia or other psychiatric illness that prevents the patient from giving informed
 consent (Mini Mental Status Exam score less than 24).

 6. Legal incapacity or limited legal capacity.

 7. Presence of severe renal disease BUN 50% greater than normal, Patients must have
 evidence from their PCP or Urologists of normal PSA and urodynamic tests within the
 last 12 month. Normal BUN levels should be within a range of 5 to 20 mg/ d L and
 creatinine between .7 and 1.4 mg/ d L. Labs will be requested from PCP.

 8. Presence of major hepatic impairment (Cirrhosis, Viral Hepatitis, Nonalcoholic
 Steatohepatitis, Wilson's disease, or Hemochromatosis). LFT must show non-clinically
 significant results (Albumin range 3.0-6.0; Alkaline phosphatase range 40-150; ALT
 range 0-55; AST range 5-34).

 9. Presence of severe daytime sleepiness.

 10. Present complaints of somnolence, dizziness, blurred vision, bleeding tendencies,
 cardiac abnormalities.

 11. Patients taking dopamine agonists for any condition other than RLS. -